Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370836 | 0.86 | ALDH1A1 (0.43) | LMNAMEN1KMT2AMAPTPOLB | |
| SCHEMBL17689718 | 0.83 | ABL1 (0.44) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL31636439 | 0.81 | TDP1 (0.43) | TDP1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27666406 | 0.77 | KDM4E (0.51) | TDP1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18756750 | 0.76 | XDH (0.51) | TDP1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10610948 | 0.76 | ABL1 (0.49) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL31636714 | 0.74 | ABL1 (0.45) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL31636728 | 0.74 | PTGS2 (0.48) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL4955520 | 0.74 | TDP1 (0.54) | TDP1LMNAKMT2AMAPTPOLB | |
| SCHEMBL6304243 | 0.73 | PTGER4 (0.39) | LMNAMEN1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137158-A1 | DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-1608633-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| CN-100588650-C | Non-nucleoside reverse transcriptase inhibitors I for the treatment of HIV mediated diseases | HOFFMANN LA ROCHE | 2010-02-10 | — | — | CN | disclosed |
| CN-100469769-C | Benzyl-pyridazinons as reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (CH) | 2009-03-18 | — | — | CN | disclosed |
| US-7348345-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070179157-A1 | Nonnucleoside reverse transcriptase inhibitors | DUNN JAMES P | 2007-08-02 | — | — | US | disclosed |
| US-7208509-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| CN-1764649-A | Benzyl-pyridazinones as reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (CH) | 2006-04-26 | — | — | CN | disclosed |
| CN-1759104-A | Non-nucleoside reverse transcriptase inhibitors I for the treatment of HIV mediated diseases | HOFFMANN LA ROCHE (CH) | 2006-04-12 | — | — | CN | disclosed |
| EP-1608633-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | F. Hoffmann-La Roche AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| EP-1608629-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-10-07 | — | — | US | disclosed |
| WO-2004085411-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085406-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192704-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192704-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLA1, REV1 | TDP1 34/4885LMNA 1842/4885MEN1 4511/4885 |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLR2A, POLR2E | TDP1 53/4885LMNA 1382/4885MEN1 4616/4885 |
| US-20070179157-A1 | Nonnucleoside reverse transcriptase inhibitors | RRM2, RRM2B, SAMHD1 | TDP1 124/4885LMNA 2329/4885MEN1 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.